TABLE 3.
Patients with and Without ASP Progression
| ASP Progression
|
|||
|---|---|---|---|
| Variables | Present (n = 11) | Absent (n = 94) | p Value |
| Recipient profile | |||
|
| |||
| Age, yrs | 49 (40–55) | 52 (42–61) | 0.25 |
| Male | 72.7 | 68.1 | 0.75 |
| Body mass index, kg/m2 | 29.7 (26.0–31.8) | 25.0 (22.5–27.8) | 0.02 |
| Cytomegalovirus IgG positive | 63.6 | 68.1 | 0.77 |
| Diabetes mellitus | 18.2 | 13.8 | 0.70 |
| Hypertension | 9.1 | 39.4 | 0.03 |
| Hyperlipidemia | 27.3 | 27.7 | 0.98 |
| Ischemic cardiomyopathy | 27.3 | 23.4 | 0.78 |
| Statins at 1 year | 90.9 | 93.6 | 0.74 |
| Antidiabetic medications* at 1 year | 54.6 | 27.7 | 0.08 |
| Insulin at 1 year | 45.5 | 19.2 | 0.06 |
| Total cholesterol at 1 year, mg/dl | 172 (153–206) | 169 (147–190) | 0.80 |
| Triglycerides at 1 year, mg/dl | 151 (107–172) | 109 (81–182) | 0.25 |
| LVEF at 1 year, % | 61.0 (56.2–66.1) | 61.0 (57.0–64.5) | 0.99 |
| Acute cellular rejection ≥2R† | 63.6 | 22.3 | 0.006 |
| pAMR ≥2† | 0 | 1.1 | 0.64 |
| De novo DSA | 18.2 | 8.5 | 0.35 |
| Severe rejection‡ | 18.2 | 3.2 | 0.07 |
| Immunosuppressive regimen§ | |||
| rATG | 9.1 | 40.4 | 0.03 |
| Tacrolimus | 18.2 | 54.3 | 0.02 |
| Sirolimus | 36.4 | 10.6 | 0.04 |
|
| |||
| Donor profile | |||
|
| |||
| Age, yrs | 40 (25–50) | 24 (19–40) | 0.03 |
| Male | 81.8 | 72.3 | 0.49 |
| Donor-recipient sex mismatch | 9.1 | 23.4 | 0.24 |
| Cold ischemic time, min | 203±43 | 224±50 | 0.18 |
|
| |||
| Baseline IVUS indexes | |||
|
| |||
| Vessel volume, mm3/mm | 16.4±2.3 | 14.8±3.7 | 0.16 |
| Lumen volume, mm3/mm | 12.8±3.1 | 12.2±3.0 | 0.56 |
| Intimal volume, mm3/mm | 3.5 (3.1–3.8) | 2.3 (1.8–3.0) | 0.003 |
| Percent intimal volume, % | 22.2 (16.8–26.8) | 16.3 (12.6–19.8) | 0.017 |
| Maximum intimal thickness, mm | 1.41 (1.18–1.86) | 0.58 (0.40–0.92) | <0.0001 |
| Donor atherosclerosis | 100 | 56.4 | 0.0006 |
Values are median (IQR), %, or mean ± SD.
*
Oral antidiabetic drugs and/or insulin.
†
1 or more episodes of grade ≥2R or 2 during the first year post-transplant.
‡
Severe rejection with hemodynamic compromise, defined as a decrease in relative LVEF >25%.
§
Primarily used during the first year post-transplant.